Whether to implant a defibrillator or not? The Possibility of Using the MADIT-ICD Benefit Score Calculator in Real Practice

Aim. To study the predictive capabilities of the MADIT-ICD Benefit Score calculator in assessing the benefit of implantable cardioverter defibrillator (ICD) placement for the primary prevention of sudden cardiac death (SCD).

Material and methods. This study included 388 patients with NYHA II-IV functional class chronic heart failure (CHF) with a left ventricular ejection fraction (LVEF) ≤35 % who underwent ICD placement for the primary prevention of SCD. Patients were followed up for two years to record the endpoints of first-time paroxysmal sustained ventricular tachyarrhythmia (VT) or non-arrhythmic death.

Results. According to the results of calculation with the MADIT-ICD Benefit Score calculator, 276 (71 %) patients had a high risk of VT (score ≥7) and 150 (39 %) had a high risk of non-arrhythmic death (score ≥3). 336 (94%) patients would benefit from an ICD: 148 (38 %) with a high level of probability and 218 (56 %) with a medium level of probability. According to the incidence of endpoints, VT episodes predominated in the low-ICD benefit group (36%), while the high-ICD benefit group had a relatively high incidence of non-arrhythmic death (12%).

Conclusion. The results obtained for a cohort of Russian patients with CHF and reduced LVEF indicated that the use of the MADIT-ICD Benefit Score in routine clinical practice does not improve the stratification of SCD risk compared to the traditional approach to selecting patients with CHF for ICD based on the LVEF value.

1. Zeppenfeld K, Tfelt-Hansen J, De Riva M, Winkel BG, Behr ER, Blom NA et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2022;43(40):3997–4126. DOI: 10.1093/eurheartj/ehac262

2. Ilov N.N., Palnikova O.V., Stompel D.R., Nikolaeva E.V., Nechepurenko A.A. Risk stratification of sudden cardiac death in heart failure patients: is left ventricular ejection fraction alone sufficient? Russian Journal of Cardiology. 2021;26(1):172–9. DOI: 10.15829/1560-4071-2021-3959

3. Li X, Fan X, Li S, Sun W, Shivkumar K, Zhao S et al. A Novel Risk Stratification Score for Sudden Cardiac Death Prediction in MiddleAged, Nonischemic Dilated Cardiomyopathy Patients: The ESTIMATED Score. Canadian Journal of Cardiology. 2020;36(7):1121–9. DOI: 10.1016/j.cjca.2019.11.009

4. Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I. Applicability of a Risk Score for Prediction of the Long-Term (8-Year) Benefit of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology. 2012;59(23):2075–9. DOI: 10.1016/j.jacc.2012.02.036

5. Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ et al. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. Journal of the American College of Cardiology. 2017;69(21):2606–18. DOI: 10.1016/j.jacc.2017.03.568

6. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083

7. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine. 2002;346(12):877–83. DOI: 10.1056/NEJMoa013474

8. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. New England Journal of Medicine. 2009;361(14):1329–38. DOI: 10.1056/NEJMoa0906431

9. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP et al. Reduction in inappropriate therapy and mortality through ICD programming. New England Journal of Medicine. 2012;367(24):2275–83. DOI: 10.1056/NEJMoa1211107

10. Younis A, Goldberger JJ, Kutyifa V, Zareba W, Polonsky B, Klein H et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. European Heart Journal. 2021;42(17):1676–84. DOI: 10.1093/eurheartj/ehaa1057

11. Younis A, Goldenberg I. Extending the MADIT-ICD benefit score to heterogenous heart failure populations. European Heart Journal. 2021;42(46):4774–5. DOI: 10.1093/eurheartj/ehab162

12. Ilov N.N., Surikova O.N., Boytsov S.A., Zorin D.A., Nechepurenko A.A. Possibilities for predicting ventricular tachyarrhythmias in patients with heart failure with reduced ejection fraction based on surface electrocardiography. First results from a single-center prospective study. Russian Journal of Cardiology. 2021;26(12):80–9. DOI: 10.15829/1560-4071-2021-4661

13. Ilov N.N., Stompel D.R., Boytsov S.A., Palnikova O.V., Nechepurenko A.A. Perspectives on the Use of Transthoracic Echocardiography Results for the Prediction of Ventricular Tachyarrhythmias in Patients with Non-ischemic Cardiomyopathy. Rational Pharmacotherapy in Cardiology. 2022;18(3):251–60. DOI: 10.20996/1819-6446-2022-06-01

14. Willy K, Köbe J, Reinke F, Rath B, Ellermann C, Wolfes J et al. Usefulness of the MADIT-ICD Benefit Score in a Large Mixed Patient Cohort of Primary Prevention of Sudden Cardiac Death. Journal of Personalized Medicine. 2022;12(8):1240. DOI: 10.3390/jpm12081240

15. Zareba W, Daubert JP, Beck CA, Huang DT, Alexis JD, Brown MW et al. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators. Journal of the American College of Cardiology. 2018;72(6):636–45. DOI: 10.1016/j.jacc.2018.04.086